Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-08-27

Clinical Trial Update: Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus

View source ↗

Summary

Post-marketing surveillance results for Esgliteo in Korean patients with Type 2 diabetes mellitus have been completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Esgliteo

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Status: COMPLETED | Results posted: 2025-08-27